| ²é¿´: 5454 | »Ø¸´: 86 | |||
| ¡¾½±Àø¡¿ ±¾Ìû±»ÆÀ¼Û79´Î£¬×÷Õß°×¹â35Ôö¼Ó½ð±Ò 61.8 ¸ö | |||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | |||
[×ÊÔ´]
ÃÀ¹úFDA¹ËÎÊÒ©Æ·Éú²úÆóÒµÑéÖ¤Åàѵ
|
|||
|
FUNDAMENTALS AND ESSENTIALS OF VALIDATION ÑéÖ¤»ù´¡¼°ÊµÖÊ Michael Anisfeld £¨Dr.Âó¿Ë.°²Ë¹·Æ¶ûµÃ£© Globepharm Consulting INTRODUCTION + REGULATORY ENVIRONMENT ½éÉÜ£«·¨¹æ»·¾³ VALIDATION BASICS ÑéÖ¤»ù´¡ÖªÊ¶ VALIDATION MASTER PLANS ÑéÖ¤Ö÷Îļþ PROCESS VALIDATION ¹¤ÒÕÑéÖ¤ UTILITIES VALIDATION ¹«ÓÃϵͳÑéÖ¤ CLEANING VALIDATION Çå½àÑéÖ¤ COMPUTER VALIDATION ¼ÆËã»úϵͳÑéÖ¤ ANALYTICAL METHOD VALIDATION ·ÖÎö·½·¨ÑéÖ¤ CASE STUDY °¸ÀýÑо¿ |
» ÊÕ¼±¾ÌûµÄÌÔÌûר¼ÍƼö
ÑéÖ¤ |
» ²ÂÄãϲ»¶
ÐÂ¼ÓÆÂ¹úÁ¢´óѧҩѧϵ»¯Ñ§ÉúÎïѧ¿ÎÌâ×éÕÐPhD
ÒѾÓÐ14È˻ظ´
Çë½Ìõ£°·ËõºÏ·´Ó¦
ÒѾÓÐ4È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ123È˻ظ´
Ò»Ö¾Ô¸´óÁ¬Àí¹¤ÖÆÒ©¹¤³Ìר˶086002£¬±¾¿Æ211£¬×Ü·Ö342
ÒѾÓÐ0È˻ظ´
ÖÆÒ©¹¤³ÌרҵÕÐÊÕµ÷¼Á£¬ÒªÇó¹ý¹ú¼ÒÏß
ÒѾÓÐ0È˻ظ´
ÎåÒØ´óѧҩÎﻯѧÉúÎïѧÍŶÓ-ÀîÀ¼Çå¿ÎÌâ×éÕÐÊÕµ÷¼ÁѧÉú
ÒѾÓÐ0È˻ظ´
Çóµ°°×ÍÆ¼ö£¬ÓÃÓÚʵÑé½ÌѧÖе°°×Ò©ÎïµÄ±í´ï
ÒѾÓÐ0È˻ظ´
Çóµ°°×ÍÆ¼ö£¬ÓÃÓÚʵÑé½ÌѧÖе°°×Ò©ÎïµÄ±í´ï
ÒѾÓÐ0È˻ظ´
Çóµ°°×ÍÆ¼ö£¬ÓÃÓÚʵÑé½ÌѧÖе°°×Ò©ÎïµÄ±í´ï
ÒѾÓÐ2È˻ظ´
342Ò»Ö¾Ô¸´ó¹¤ÖÆÒ©×¨Ë¶£¬±¾¿Æ211£¬Çóµ÷¼Á
ÒѾÓÐ1È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
ÔõÑù´ÓÃÀ¹úFDAÍøÕ¾ÉϲéÕÒ¼°ÏÂÔØÒ©Æ·ËµÃ÷Ê飿
ÒѾÓÐ11È˻ظ´
¡¾×ÊÔ´¡¿FDA-GMPÅàѵ×ÊÁÏ--ÔÁÏÒ©Éú²úÖеÄÈ·ÈÏÓëÑéÖ¤£¨ÖÐÓ¢¶ÔÕÕ£©
ÒѾÓÐ144È˻ظ´
¡¾×ªÌû¡¿º£ÆÕÈð¡°¶À¼ÒFDAÈÏÖ¤¡±µÄ½âÎö
ÒѾÓÐ9È˻ظ´
11Â¥2011-05-28 20:46:41
2Â¥2011-05-21 13:48:03
5Â¥2011-05-23 17:05:37
¼òµ¥»Ø¸´
yamaya4Â¥
2011-05-23 13:21
»Ø¸´
ÈýÐÇºÃÆÀ ¶¥Ò»Ï£¬¸Ðл·ÖÏí£¡
ssyy98766Â¥
2011-05-27 16:22
»Ø¸´
ÎåÐÇºÃÆÀ ¶¥Ò»Ï£¬¸Ðл·ÖÏí£¡
zhanglianglu7Â¥
2011-05-27 21:24
»Ø¸´
ÎåÐÇºÃÆÀ ¶¥Ò»Ï£¬¸Ðл·ÖÏí£¡
jxjun1888Â¥
2011-05-28 10:12
»Ø¸´
ÎåÐÇºÃÆÀ ¶¥Ò»Ï£¬¸Ðл·ÖÏí£¡
lucacai10Â¥
2011-05-28 19:45
»Ø¸´
ÎåÐÇºÃÆÀ ¶¥Ò»Ï£¬¸Ðл·ÖÏí£¡
lzxfil12Â¥
2011-05-29 10:45
»Ø¸´
ÎåÐÇºÃÆÀ ¶¥Ò»Ï£¬¸Ðл·ÖÏí£¡
ÎÞË«¹úÊ¿13Â¥
2011-05-30 15:33
»Ø¸´
ÎåÐÇºÃÆÀ ¶¥Ò»Ï£¬¸Ðл·ÖÏí£¡
·½·½33814Â¥
2011-06-02 14:05
»Ø¸´
ÎåÐÇºÃÆÀ ¶¥Ò»Ï£¬¸Ðл·ÖÏí£¡














»Ø¸´´ËÂ¥